Showing 4181-4190 of 5911 results for "".
- Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Trial of ADX‑2191 in Patients with RPhttps://modernod.com/news/aldeyra-therapeutics-announces-improvement-from-baseline-in-retinal-function-in-phase-2-clinical-trial-of-adx2191-in-patients-with-rp/2481703/Aldeyra Therapeutics announced positive topline results from the phase 2 clinical trial of intravitreal ADX-2191 (methotrexate injection, USP), an investigational drug candidate, in patients with retinitis pigmentosa (RP). Relative to baseline, the clinical trial demonstrated statistically s
- Visgenx Announces Positive Results from a Key Translational Study for its Gene Therapy Candidate for Dry AMDhttps://modernod.com/news/visgenx-announces-positive-results-from-a-key-translational-study-for-its-gene-therapy-candidate-for-dry-amd/2481700/Visgenx announced positive data from a non-human primate study. The translational study used a single subretinal injection to deliver VGX-0111 (carrying an ELOVL2 transgene) to investigate whether VGX-0111 expresses in the target tissues and causes an increase in certain very long chain
- Ciliatech Presents 2-Year Postoperative Results on New Cilio-Scleral Surgical Approach for Treating Glaucomahttps://modernod.com/news/ciliatech-presents-2-year-postoperative-results-on-new-cilio-scleral-surgical-approach-for-treating-glaucoma/2481698/Ciliatech announced it will present the preliminary results of the second 2-year postoperative clinical trial (SAFARI II) on its Cilia-scleral Interposition Device (CID) during the World Glaucoma Congress, taking place this week. Ciliatech will present results showing sta
- FDA Does Not Approve Regeneron's High-Dose Aflibercepthttps://modernod.com/news/fda-does-not-approve-regenerons-high-dose-aflibercept/2481695/Citing "an ongoing review of inspection findings at a third-party filler," the FDA declined to approve Regeneron's aflibercept 8 mg for the treatment of patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR).</
- Myra Vision Announces Funding to Advance Calibreye Surgical Treatment for Glaucoma Patientshttps://modernod.com/news/myra-vision-raises-money-to-advance-calibreye-surgical-treatment-for-glaucoma-patients/2481694/Myra Vision, which is a Shifamed portfolio company, announced the closing of its $25 million Series B financing to further product development, scale manufacturing capabilities, and support first-in-human investigation of the company's Calibreye System, a novel treatm
- iOR Publishes Ophthalmic Office-Based Surgery Safety Studyhttps://modernod.com/news/ior-publishes-ophthalmic-office-based-surgery-safety-study/2481693/Office-based lens surgery can be performed safely, with adverse event rates similar to or lower than those in the published literature, according to a study published by iOR Partner
- Luminopia Raises Money to Support Full Commercial Rollout of Amblyopia Therapeutichttps://modernod.com/news/luminopia-raises-money-to-support-full-commercial-rollout-of-amblyopia-therapeutic/2481692/Luminopia announced it has raised an additional $16 million in new capital to support the full commercial rollout later this year of the company’s lead product, Luminopia, a software-based therapeutic for amblyopia, the leading cause of vision loss among children. Luminopia w
- Bruder Healthcare Expands Dry Eye Portfolio with Eye Care Distribution of AllerFocus Percutaneous Allergy Testhttps://modernod.com/news/bruder-healthcare-expands-dry-eye-portfolio-with-eye-care-distribution-of-allerfocus-percutaneous-allergy-test/2481689/Bruder Healthcare announced an eye care industry distribution agreement with Tallahassee, Florida-based AllerFocus for its Percutaneous Allergy Test, a needle-free allergy screening for 78 of the most common airborne and environmental allergens. Financial terms of the deal w
- Study Uncovers Novel Synaptic Intricacies Inside the Retinahttps://modernod.com/news/study-uncovers-novel-synaptic-intricacies-inside-the-retina/2481687/A Northwestern Medicine study has uncovered novel cellular mechanisms within the retina, findings that researchers say could help advance the development of targeted therapeutics for diseases and conditions impacting vision. The findings were
- FDA Rejects Aldeyra's NDA for Rare Eye Cancer Drug ADX-2191https://modernod.com/news/fda-rejects-aldeyras-nda-for-rare-eye-cancer-drug-adx-2191/2481684/The FDA issued a Complete Response Letter to Aldeyra Therapeutics for the NDA of ADX-2191 (methotrexate for injection, USP), an investigational drug candidate for the treatment of primary vitreoretinal lymphoma (PVRL). Although no safety or manufacturing issues with ADX-2191 w